Rising Costs Push Indian Pharma MSMEs to Seek Input Price Caps

Indian pharmaceutical manufacturers are seeking input price caps as rising costs put pressure on smaller players across the sector.

The push for input price caps reflects growing concern among Indian pharma MSMEs struggling to manage steep increases in production expenses while drug prices remain tightly regulated.

Industry stakeholders say the cost of key raw materials, including active pharmaceutical ingredients, solvents, and packaging, has surged sharply, in some cases by 200–300 percent. These increases are linked to global supply chain disruptions, geopolitical tensions, and higher transportation costs. For smaller pharma firms, which operate on thin margins, this spike is becoming unsustainable.

Also Read: Ozempic Patent Expiry Drives Surge in Pharma Stocks Ahead of Launch

Manufacturers have urged the government to intervene by capping prices of essential inputs and setting up a dedicated task force to monitor supply and pricing issues. They warn that without timely support, many small units may be forced to cut production or shut down operations altogether.

The situation is further strained by limited flexibility in drug pricing. Annual price revisions for many medicines remain minimal, preventing companies from passing on rising costs to consumers. This gap between escalating input costs and controlled medicine prices is intensifying financial stress across the sector.

Experts caution that continued pressure could disrupt the supply of essential medicines and accelerate industry consolidation, leaving smaller players at risk. The demand for input price caps underscores the urgent need to balance affordability with the sustainability of India’s pharmaceutical ecosystem.